Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Phio Pharmaceuticals Corp PHIO

Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:PHIO)

Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

GlobeNewswire 1 day ago

Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)

GlobeNewswire 7 days ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)

GlobeNewswire 12 days ago

National Spotlight Features Phio's Innovative RNAi Technology Platform

GlobeNewswire April 3, 2024

Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update

GlobeNewswire April 2, 2024

Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

GlobeNewswire March 21, 2024

Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research

GlobeNewswire March 13, 2024

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company's Intellectual Property Position in Treating Aging Skin and Skin Disorders

GlobeNewswire March 6, 2024

Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies

GlobeNewswire January 31, 2024

Opinion & Analysis (NDAQ:PHIO)

No current opinion is available.

Bullboard Posts (NDAQ:PHIO)

Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Mo

BREAKING NEWS: $PHIO Why Is Penny Stock Phio Pharmaceuticals Trading Higher On Monday? | BenzingaPhio Pharmaceuticals Corp@(NASDAQ:PHIO)...
whytestocks - 1 day ago

Intratumoral Injection of Phio's PH-762 significantly inhibi

Breaking News: $PHIO Intratumoral Injection of Phio's PH-762 significantly inhibits tumor growth in murine tumor models and may...
whytestocks - 1 day ago

Phio Pharmaceuticals Announces Data Showing INTASYL May Resu

NEWS: $PHIO Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies...
whytestocks - January 31, 2024

Phio ...warrants are exercised....dilution

Cha ching!!!!!!!!!
Iseneschal - December 7, 2023

PHIO.....kaboom

Lets go
Iseneschal - December 6, 2023

PHIO.....ten to one this will be huge in AH

I just had to sell and crystalize my profit Cheers to all !!!!!
Iseneschal - October 11, 2023